Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Illumina Inc (NASDAQ:ILMN)

163.37
Delayed Data
As of Feb 17
 +2.07 / +1.28%
Today’s Change
119.37
Today|||52-Week Range
186.88
+27.59%
Year-to-Date
Why Illumina Is a Buy
Feb 17 / MotleyFool.com - Paid Partner Content
Better Buy: Illumina or Gilead Sciences?
Feb 13 / MotleyFool.com - Paid Partner Content
3 Stocks Set to Profit From the Rise of China
Feb 15 / MotleyFool.com - Paid Partner Content
Biotech ETFs Powered by Q4 Earnings
Feb 10 / Zacks.com - Paid Partner Content
What Illumina's New Products Mean for 2017 and Beyond
Feb 14 / MotleyFool.com - Paid Partner Content
Better Buy: Illumina, Inc. vs. Thermo Fisher Scientific
Feb 08 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close161.30
Today’s open161.30
Day’s range161.12 - 163.46
Volume892,449
Average volume (3 months)1,505,613
Market cap$23.9B
Dividend yield--
Data as of 4:00pm ET, 02/17/2017

Growth & Valuation

Earnings growth (last year)-0.97%
Earnings growth (this year)+9.37%
Earnings growth (next 5 years)+11.00%
Revenue growth (last year)+8.05%
P/E ratio54.8
Price/Sales7.90
Price/Book10.87

Competitors

 Today’s
change
Today’s
% change
BIVVBioverativ Inc+3.35+7.60%
TECHBio-Techne Corp+0.23+0.22%
NBIXNeurocrine Bioscienc...+0.90+2.09%
BLUEbluebird bio Inc+0.55+0.72%
Data as of 4:00pm ET, 02/17/2017

Financials

Next reporting dateApril 24, 2017
EPS forecast (this quarter)$0.65
Annual revenue (last year)$2.4B
Annual profit (last year)$454.1M
Net profit margin18.93%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Francis A. deSouza
Chief Financial Officer &
Senior Vice President
Sam A. Samad
Corporate headquarters
San Diego, California

Forecasts


Search for Jobs